BIOTE CORP -A
BTMDNASDAQTrading Snapshot
- Day Range
- $1.43 – $1.47
- 52-Week Range
- $1.27 – $3.62
- Volume
- $2.49B
- Avg Volume
- $2.15B
- Shares Outstanding
- 37.6M
- Next Earnings
- Sep 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $192M
- Last Q Revenue
- $44M
- P/E Ratio
- 3.5
- P/S Ratio
- 0.3x
- EPS (TTM)
- $0.44
- Dividend Yield
- —
Why Investors Own BTMD
- ✓High-growth profile — revenue up +57.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIOTE CORP -A
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $1.5
B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $2 to $1.5.
TD Cowen Maintains Buy on Biote, Lowers Price Target to $2
TD Cowen analyst Jonna Kim maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $2.5 to $2.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) stock rose
biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
biote Corp. (BTMD) Q2 2026 Earnings Call August 5, 2026 5:00 PM EDTCompany ParticipantsRobert Peterson - Interim CEO, CFO & Chief Business...
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences (NASDAQ:CAI)
Biote FY2026 Revenue expected to be more than $175.000M vs $190.807M Est
Biote (NASDAQ:BTMD) FY2026 Revenue expected to be more than $175.000M vs $190.807M Est